Ovarian reserve and markers after chemotherapy in young women with early-stage breast cancer
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260590Keywords:
Breast cancer, Ovarian reserve, Chemotherapy, FertilityAbstract
Background: The aim of the study was to compare ovarian reserve and its markers between young women who received chemotherapy for early-stage breast cancer and healthy controls.
Methods: This cross-sectional study was conducted at Gülhane Military Medical Academy (GATA, currently Ankara Gülhane Training and Research Hospital), Ankara, Türkiye, between December 2010 and October 2011. Ovarian reserve was evaluated in 34 women with early-stage breast cancer who resumed regular menstruation after chemotherapy and compared with 34 age- and gravida-matched healthy controls. Main outcome measures included antral follicle count (AFC), total ovarian volume, anti-Müllerian hormone (AMH), FSH, and estradiol (E2) levels on days 2 or 3 of the menstrual cycle.
Results: The median AFC was 5 in the cancer group and 7 in the controls. AMH, AFC, ovarian volume, and FSH levels significantly differed between groups, favoring the controls. A significant difference in E2 levels was also noted. AFC and AMH were strongly correlated (r=0.84 and r=0.74, respectively). Multivariate logistic regression identified AFC as the strongest predictor of AMH.
Conclusions: Chemotherapy for early-stage breast cancer is associated with reduced ovarian reserve in young women despite the continuation of menstruation.
Metrics
References
Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159-182. DOI: https://doi.org/10.1016/j.annonc.2023.11.016
Su HI. Measuring ovarian function in young cancer survivors. Minerva Endocrinol. 2010;35:259-70.
Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson hospital and tumor institute. NCI Monogr. 1986;1:105-9.
Velez MP, Richardson H, Baxter NN. Risk of infertility in female adolescents and young adults with cancer: a population-based cohort study. Hum Reprod. 2021;36:1981-1988. DOI: https://doi.org/10.1093/humrep/deab036
Baxter NN, Sutradhar R, DelGuidice ME. A population-based study of rates of childbirth in recurrence-free female young adult survivors of non-gynecologic malignancies. BMC Cancer. 2013;13:30. DOI: https://doi.org/10.1186/1471-2407-13-30
Woodruff TK. Oncofertility: a grand collaboration between reproductive medicine and oncology. Reproduction. 2015;150:S1-10. DOI: https://doi.org/10.1530/REP-15-0163
Korkidakis A, Lajkosz K, Green M, et al. Patterns of referral for fertility preservation among female adolescents and young adults with breast cancer: a population-based study. J Adolesc Young Adult Oncol. 2020;9:546-47. DOI: https://doi.org/10.1089/jayao.2018.0102.correx
Ruddy KJ, O'Neill A, Miller KD. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat. 2014;144:591-7. DOI: https://doi.org/10.1007/s10549-014-2891-0
Omranipour R, Ahmadi-Harchegani F, Saberi A, et al. A new model including AMH cut-off levels to predict post-treatment ovarian function in early breast cancer: a prospective cohort study. Arch Iran Med. 2024;27:96-104. DOI: https://doi.org/10.34172/aim.2024.15
Su HC, Haunschild C, Chung K. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer. 2014;120:3691-8. DOI: https://doi.org/10.1002/cncr.28942
Partridge AH, Ruddy KJ, Gelber S. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010;94:638-44. DOI: https://doi.org/10.1016/j.fertnstert.2009.03.045
Ünal Ç, Ordu Ç, Özmen T. Evaluation of anti-mullerian hormone levels, antral follicle counts, and mean ovarian volumes in chemotherapy-induced amenorrhea among breast cancer patients: a prospective clinical study. Curr Oncol. 2023;30:9217-29. DOI: https://doi.org/10.3390/curroncol30100666
Peluso C, Oliveira R, Laporta GZ. Are ovarian reserve tests reliable in predicting ovarian response? Results from a prospective, cross-sectional, single-center analysis. Gynecol Endocrinol. 2021;37:358-66. DOI: https://doi.org/10.1080/09513590.2020.1786509
Turnbull AK, Patel S, Martinez-Perez C. Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer. Breast Cancer Res Treat. 2021;186:237-45. DOI: https://doi.org/10.1007/s10549-020-05951-5
Stearns V, Schneider B, Henry NL, et al. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer. 2006;6:886-93. DOI: https://doi.org/10.1038/nrc1992
Nitz U, Gluz O, Clemens M. West German study PlanB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol. 2019;37:799-808. DOI: https://doi.org/10.1200/JCO.18.00028
Petrek JA, Naughton MJ, Case LD. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24:1045-51. DOI: https://doi.org/10.1200/JCO.2005.03.3969
Furlanetto J, Marmé F, Seiler S. Chemotherapy-induced ovarian failure in young women with early breast cancer: prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. Eur J Cancer. 2021;152:193-203. DOI: https://doi.org/10.1016/j.ejca.2021.04.038
Iwamoto T, Hara F, Uemura Y. NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy. Breast Cancer Res Treat. 2020;182:325-32. DOI: https://doi.org/10.1007/s10549-020-05692-5
Curigliano G, Burstein HJ, Gnant M. Understanding breast cancer complexity to improve patient outcomes: the St Gallen international consensus conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol. 2023;34:970-86. DOI: https://doi.org/10.1016/j.annonc.2023.08.017
Downloads
Published
How to Cite
Issue
Section
